Biogen (BUE:BIIB) Cyclically Adjusted FCF per Share: ARS2,524.25 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:BIIB Biogen Inc BUE:BIIB
60 GF Score
Price ARS24,940.00
GF Value ARS23,713.91
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Biogen Cyclically Adjusted FCF per Share?

Biogen BUE:BIIB +1.80% 60 Cyclically Adjusted FCF per Share is ARS2,524.25 as of Mar. 2026. GuruFocus rates BUE:BIIB with a GF Score™ of 60/100 and a GF Value™ of ARS23,713.91 (Fairly Valued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Biogen's adjusted free cash flow per share for the three months ended in Mar. 2026 was ARS5,269.801. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ARS2,524.25 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biogen's average Cyclically Adjusted FCF Growth Rate was 0.80% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 5.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 7.50% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 15.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Biogen was 157.10% per year. The lowest was 5.00% per year. And the median was 25.00% per year.

As of today (2026-07-25), Biogen's current stock price is ARS24940.00. Biogen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ARS2,524.25. Biogen's Cyclically Adjusted Price-to-FCF of today is 9.88.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biogen was 47.68. The lowest was 5.21. And the median was 16.45.


Biogen  (BUE:BIIB) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Biogen's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=24940.00/2524.25
=9.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Biogen was 47.68. The lowest was 5.21. And the median was 16.45.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Biogen Cyclically Adjusted FCF per Share Related Terms


Biogen Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Biogen's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Cyclically Adjusted FCF per Share Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 278.92 491.97 1,570.63 1,977.25 2,595.00

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,232.77 2,044.25 2,660.41 2,595.00 2,524.25

BUE:BIIB vs OGN, AMRN, SCLX: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted Price-to-FCF falls into.


BUE:BIIB
60GF Score
Biogen Inc BUE:BIIB
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=5269.801/330.2130*330.2130
=5,269.801

Current CPI (Mar. 2026) = 330.2130.

Biogen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 56.709 241.018 77.696
201609 48.313 241.428 66.080
201612 102.172 241.432 139.743
201703 -59.269 243.801 -80.276
201706 65.766 244.955 88.656
201709 111.619 246.819 149.332
201712 110.078 246.524 147.447
201803 119.200 249.554 157.727
201806 100.398 251.989 131.564
201809 281.634 252.439 368.403
201812 314.428 251.233 413.275
201903 264.383 254.202 343.438
201906 417.012 256.143 537.601
201909 487.242 256.759 626.633
201912 568.806 256.974 730.919
202003 432.298 258.115 553.050
202006 784.375 257.797 1,004.708
202009 518.074 260.280 657.272
202012 -247.203 260.474 -313.389
202103 400.066 264.877 498.748
202106 729.188 271.696 886.238
202109 489.163 274.310 588.852
202112 527.065 278.802 624.256
202203 75.582 287.504 86.810
202206 574.242 296.311 639.943
202209 577.583 296.808 642.589
202212 -302.554 296.797 -336.618
202303 522.038 301.836 571.117
202306 659.794 305.109 714.081
202309 1,219.991 307.789 1,308.874
202312 -130.395 306.746 -140.371
202403 2,496.318 312.332 2,639.232
202406 3,579.545 314.175 3,762.274
202409 5,241.087 315.301 5,488.962
202412 4,808.403 315.605 5,030.963
202503 1,543.063 319.799 1,593.312
202506 1,086.881 322.561 1,112.665
202509 11,272.149 324.800 11,460.007
202512 3,939.616 324.054 4,014.493
202603 5,269.801 330.213 5,269.801

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ARS2,524.25 mean?
Biogen (BUE:BIIB) has a Cyclically Adjusted FCF per Share of ARS2,524.25 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Biogen and its competitors.
Is Biogen's Cyclically Adjusted FCF per Share too high?
Biogen's current Cyclically Adjusted FCF per Share is ARS2,524.25. Overall, Biogen has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Cyclically Adjusted FCF per Share compare to OGN and AMRN?
Biogen's Cyclically Adjusted FCF per Share of ARS2,524.25 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Biogen and its competitors. Biogen's current Cyclically Adjusted FCF per Share is ARS2,524.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (BUE:BIIB) is currently considered Fairly Valued. The stock's GF Value™ is ARS23,713.91, compared to a current price of ARS24,940.00 — trading 5.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is ARS2,524.25. Biogen's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Biogen (BUE:BIIB), the current Cyclically Adjusted FCF per Share is ARS2,524.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (BUE:BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of ARS24,940.00 is trading 5.2% above its estimated GF Value™ of ARS23,713.91. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for BUE:BIIB:

  • Cyclically Adjusted FCF per Share: ARS2,524.25
  • GF Value™: ARS23,713.91 vs. price of ARS24,940.00 (5.2% above fair value)
  • GF Score™: 60/100 with 7 warning signs

No single metric tells the full story. See the BUE:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
60GF Score

Get the complete analysis for BUE:BIIB

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS24,940.00
Price
ARS23,713.91
GF Value